Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sellas Life Sciences Group Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SLS
Nasdaq
8731
https://www.sellaslifesciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sellas Life Sciences Group Inc
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
- Mar 26th, 2024 11:35 am
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Mar 19th, 2024 8:05 pm
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
- Mar 19th, 2024 12:47 pm
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Mar 15th, 2024 1:00 pm
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
- Mar 8th, 2024 1:00 pm
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
- Mar 1st, 2024 1:30 pm
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
- Feb 29th, 2024 1:00 pm
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
- Feb 6th, 2024 1:30 pm
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
- Jan 25th, 2024 1:45 pm
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
- Jan 10th, 2024 4:30 pm
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
- Jan 9th, 2024 1:30 pm
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
- Jan 4th, 2024 2:01 pm
SELLAS Life Sciences Announces Proposed Public Offering
- Jan 4th, 2024 1:05 am
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
- Jan 3rd, 2024 12:30 pm
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
- Dec 27th, 2023 1:55 pm
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
- Dec 21st, 2023 1:15 pm
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
- Dec 14th, 2023 1:30 pm
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
- Dec 13th, 2023 1:30 pm
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
- Dec 4th, 2023 1:47 pm
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
- Nov 29th, 2023 1:45 pm
Scroll